Mark J. Gergen

Mark J. Gergen is a declared insider at 2 companies (chief executive); the most frequent names are Poseida Therapeutics, Inc. and Mirati Therapeutics, Inc. In total, 13 filings cover trades dated from 15 January 2016 to 8 January 2025.

On the market, this insider has only sold: 1 sale. The totals exclude 1 filing filed without an amount. The rest of the record consists of 7 share grants and 4 option exercises.

Most recently, on 8 January 2025, the filings show a transaction in Poseida Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.